In a recent study, researchers have developed a new class of genetically encoded fluorescence sensors to study the dynamics of opioid peptides in the brain. These sensors, delivered via adeno-associated virus (AAV) vectors, represent a novel approach to investigating opioid signaling. The sensors, termed κLight, δLight, and µLight, are based on kappa, delta, and mu opioid receptors, respectively. The research team conducted extensive characterization of the pharmacological profiles of these sensors in mammalian cells and dissociated neurons, providing new insights into the mechanisms of opioid signaling.
The κLight sensor enabled the identification of electrical stimulation parameters that trigger endogenous opioid release, allowing researchers to map the spatiotemporal dynamics of dynorphin volume transmission in brain slices. Additionally, in vivo studies in mice demonstrated the sensors’ effectiveness in detecting optogenetically driven opioid release. The findings also revealed differential opioid release dynamics in response to conditions associated with fear and reward.
This study marks a significant advancement in understanding the spatiotemporal dynamics of opioid signaling within the brain. The AAV vector design and delivery of these sensors provide a powerful toolset for high-resolution tracking of opioid peptides, offering potential applications in research areas related to pain, stress, reward, and addiction.
Notably, the vector element used in this research has been included in PackGene’s database. Additionally, PackGene’s online piVector designer tool offers free vector design and access to the sequences for vector elements used in this research, providing valuable resources for further exploration and application in neuroscience.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
AAV Gene Therapy Revolutionizes Treatment for LCA1, Improving Vision Significantly
Innovative AAV Gene Therapy Dramatically Restores Vision in LCA1 Researchers have made a significant breakthrough in treating Leber congenital amaurosis type 1 (LCA1), a severe inherited retinal disease that causes early childhood blindness, by using an innovative...
Cellular Origins & 3P Innovation Partner to Streamline Cell and Gene Therapy Manufacturing
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has partnered with 3P innovation, an engineering company and supplier of automated fill-finish equipment, to integrate 3P...
Voyager Therapeutics Expands Gene Therapy Portfolio with Novartis License for Next-Generation Capsid
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has entered into a licensing agreement with Novartis AG (NYSE: NVS) for a novel capsid developed using Voyager’s TRACER™ capsid discovery platform. This license will...
BridgeBio ends development of gene therapy for adrenal gland disorder
BridgeBio said Tuesday night it won’t move forward with a gene therapy for a group of genetic disorders that impair adrenal glands and cause disruptions in producing cortisol. The California biotech made the decision because Phase 1/2 data were “not yet...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
